Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for COVID-19
NCT04340232Phase 3Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in coronavirus disease 2019 (COVID-19), sponsored by University of Colorado Denver. Planned start Mar 2021; status: withdrawn.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04340232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340232.